-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

PNH: Key Clinical Considerations for a Terminal Complement-Mediated Disease

Program: Product Theaters
Session: PNH: Key Clinical Considerations for a Terminal Complement-Mediated Disease
Monday, December 7, 2020, 10:30 AM-11:30 AM

Anita Hill, MD, PhD

Alexion Pharmaceuticals, Inc., Leeds, United Kingdom

Disclosures: No relevant conflicts of interest to declare.

See more of: PNH: Key Clinical Considerations for a Terminal Complement-Mediated Disease
See more of: Product Theaters